A promising new sleeping sickness treatment could dramatically change how this deadly tropical disease is managed across sub Saharan Africa. A drug called acoziborole, developed by Sanofi, has been recommended for approval by a key committee of the European Medicines Agency. If authorized and distributed widely, experts believe it could accelerate efforts to eliminate sleeping sickness within the next decade.
This breakthrough is especially important for countries such as Democratic Republic of the Congo, where the majority of cases continue to occur. With global health leaders aiming to stop transmission by 2030, the arrival of a simple single dose pill may be a turning point in the fight against this neglected tropical disease.
Sleeping sickness, medically known as human African trypanosomiasis, is a parasitic disease transmitted by the bite of infected tsetse flies. These flies live in rural regions of sub Saharan Africa and spread the parasite to humans through their bite.
According to the Centers for Disease Control and Prevention, early symptoms often resemble the flu. People may experience:
If left untreated, the parasite can invade the central nervous system and reach the brain. At this advanced stage, patients may develop confusion, personality changes, poor coordination, and a reversed sleep cycle, meaning they are awake at night and sleepy during the day. Without treatment, sleeping sickness can lead to coma and death.
Because the disease primarily affects rural and impoverished communities, it has long been described as a disease of poverty.
Although progress has been made over the past two decades, treating sleeping sickness remains difficult.
Older medications were painful to administer and carried serious side effects. In the early 2000s, newer therapies improved survival rates and safety. However, these treatments still require:
For many patients living in remote villages, traveling long distances to reach a hospital is both costly and physically exhausting. Delays in treatment increase the risk of complications and death.
This is where acoziborole could make a major difference.
Acoziborole is a new oral medication designed to treat both early and advanced stages of the most common form of sleeping sickness. Unlike previous therapies, it does not require hospitalization or spinal taps.
The treatment consists of three pills taken at once as a single dose.
This simplified regimen is one of the drug’s most revolutionary features. A single visit to a healthcare provider could be enough to diagnose and treat a patient.
The medication is approved for patients aged 12 and older and has demonstrated strong effectiveness in clinical trials.
In a 2023 clinical study involving approximately 200 patients in the Democratic Republic of the Congo and Guinea, more than 95 percent of participants were considered cured 18 months after receiving acoziborole.
These long term results are encouraging because sleeping sickness can relapse if not completely eradicated from the body.
The high cure rate, combined with ease of administration, positions acoziborole as one of the most important advances in neglected tropical disease treatment in recent years.
The committee of the European Medicines Agency recently recommended approval of acoziborole, an important regulatory milestone. This recommendation paves the way for use in affected African countries through international collaboration.
In addition, Sanofi has pledged to donate the drug to the World Health Organization. This commitment means the medication would be made available free of charge to patients in countries where sleeping sickness remains a threat.
Public health experts believe this donation model will significantly improve access and help countries move closer to elimination goals.
Sleeping sickness once surged during periods of political instability in Africa, particularly in the 1970s and 1990s. At its peak, tens of thousands of cases were reported annually.
Thanks to improved treatments, active screening campaigns, and tsetse fly control efforts, case numbers have steadily fallen.
The World Health Organization has set a target to stop transmission of the most common form of sleeping sickness by 2030.
The introduction of acoziborole may provide the final push needed to meet this ambitious goal.
One of the most remarkable aspects of this development is the possibility that sleeping sickness could become the first infectious disease controlled without the use of a vaccine.
Most major global disease elimination efforts, such as those targeting polio or measles, rely heavily on vaccination campaigns. In contrast, sleeping sickness control has depended on:
If acoziborole succeeds in simplifying treatment at scale, it could represent a historic milestone in infectious disease control.
Despite the optimism surrounding acoziborole, experts caution that elimination efforts are not complete.
Researchers are still studying where the parasite may persist in humans or animal reservoirs. There is concern that hidden pockets of infection could reignite transmission if surveillance weakens.
Continued funding, political stability, and community engagement remain essential components of success.
While the drug simplifies treatment, health systems must still identify infected individuals early to prevent spread.
The real power of acoziborole lies in its simplicity.
In many rural regions of sub Saharan Africa:
A single dose oral treatment dramatically reduces the burden on patients and healthcare systems alike. It eliminates the need for hospital beds, specialized equipment for spinal taps, and extended monitoring.
For communities that have struggled with sleeping sickness for generations, this represents hope.
The progress made against sleeping sickness highlights the importance of partnerships between pharmaceutical companies, international health organizations, and local governments.
The collaboration between Sanofi and the World Health Organization demonstrates how public private partnerships can address diseases that primarily affect low income populations.
Such neglected tropical diseases often receive limited commercial attention because they do not generate significant profits. Donation commitments and regulatory cooperation are therefore critical in ensuring equitable access.
With the 2030 elimination target approaching, global health authorities are cautiously optimistic.
If acoziborole becomes widely available and screening programs continue to operate effectively, the world may witness the near elimination of one of Africa’s most devastating parasitic diseases.
However, vigilance will remain necessary even after cases decline to very low levels. Ongoing surveillance and research are vital to prevent resurgence.
The recommendation to approve acoziborole marks a historic step in the fight against sleeping sickness. A single dose treatment that is safe, effective, and easy to administer could transform care for thousands of people living in vulnerable regions.
As cases continue to decline and global efforts intensify, the dream of eliminating human African trypanosomiasis may soon become reality.
The coming years will determine whether this innovative drug can help close the final chapter on a disease that has caused suffering for generations.
The Associated Press. Feb. 27, 2026.
Statistical data and clinical findings referenced in this article describe general medical trends and research outcomes. They do not apply to any individual person. Treatment decisions should always be made in consultation with a qualified healthcare professional. This content is for informational purposes only and is not intended to provide medical advice, diagnosis, or treatment.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.